South Korea Guillain-barre Syndrome Market Size & Outlook
Related Markets
South Korea guillain-barre syndrome market highlights
- The South Korea guillain-barre syndrome market generated a revenue of USD 8.3 million in 2024 and is expected to reach USD 13.5 million by 2030.
- The South Korea market is expected to grow at a CAGR of 8.6% from 2025 to 2030.
- In terms of segment, intravenous immunoglobulin (ivig) was the largest revenue generating therapeutics in 2024.
- Plasma Exchange is the most lucrative therapeutics segment registering the fastest growth during the forecast period.
Guillain-barre syndrome market data book summary
| Market revenue in 2024 | USD 8.3 million |
| Market revenue in 2030 | USD 13.5 million |
| Growth rate | 8.6% (CAGR from 2025 to 2030) |
| Largest segment | Intravenous immunoglobulin (ivig) |
| Fastest growing segment | Plasma Exchange |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Intravenous Immunoglobulin (IVIG), Plasma Exchange, Other Therapeutics |
Other key industry trends
- In terms of revenue, South Korea accounted for 1.1% of the global guillain-barre syndrome market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China guillain-barre syndrome market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 46.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Guillain-Barre Syndrome Market Scope
Guillain-Barre Syndrome Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| LGM Pharma | View profile | 101-250 | Nashville, Tennessee, United States, North America | https://lgmpharma.com/ |
| Octapharma AG | View profile | 10001+ | Lachen, Schwyz, Switzerland, Europe | http://www.octapharma.com/en.html |
| Cadila Pharmaceuticals | View profile | 5001-10000 | Ahmedabad, Gujarat, India, Asia | http://cadilapharma.com |
| Takeda Pharmaceutical Co Ltd | View profile | 49095 | 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 | https://www.takeda.com |
| CSL Ltd | View profile | 32000 | 655 Elizabeth Street, Melbourne, VIC, Australia, 3000 | https://www.csl.com |
| Biogen Inc | View profile | 7570 | 225 Binney Street, Cambridge, MA, United States, 02142 | https://www.biogen.com |
| Grifols SA Ordinary Shares - Class A | View profile | 23737 | Avinguda de la Generalitat, 152, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, Spain, 08174 | https://www.grifols.com |
| GSK PLC | View profile | 70200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | https://www.gsk.com |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
| Roche Holding AG | View profile | 103605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | https://www.roche.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| AbbVie Inc | View profile | 50000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | http://www.abbvieinvestor.com |
South Korea guillain-barre syndrome market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to guillain-barre syndrome market will help companies and investors design strategic landscapes.
Intravenous immunoglobulin (ivig) was the largest segment with a revenue share of 56.63% in 2024. Horizon Databook has segmented the South Korea guillain-barre syndrome market based on intravenous immunoglobulin (ivig), plasma exchange, other therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to South Korea guillain-barre syndrome market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of South Korea guillain-barre syndrome market databook
-
Our clientele includes a mix of guillain-barre syndrome market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea guillain-barre syndrome market , including forecasts for subscribers. This country databook contains high-level insights into South Korea guillain-barre syndrome market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
South Korea Therapeutics - Guillain-barre Syndrome Market size, 2024 - 2030 (US$M)
South Korea Guillain-Barre Syndrome Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
